News | July 23, 2007

Medtronic’s Prestige Artificial Disc for the Neck Now Available in the U.S.

July 24, 2007 – Medtronic’s FDA-cleared Prestige Cervical Disc is the first artificial disc commercially available in the U.S. for use in the neck. The Prestige Cervical Disc may offer patients who suffer from degenerative disc disease the potential to preserve motion at the treated level, as well as offer pain relief and function, the company says.

"The patented ball-and-trough of the Prestige Cervical Disc is designed to permit motion at the treated level," said J. Kenneth Burkus, M.D., an orthopedic surgeon at the Hughston Clinic in Columbus, Ga. "Now patients suffering from cervical degenerative disc disease (DDD) have an alternative to motion limiting spinal fusion."

The company reports that study results involving 541 patients showed that the Prestige Cervical Disc had superior outcomes in neurological success, as well as overall success, a measurement that includes several safety and effectiveness outcomes, when compared to spinal fusion. The study also showed equivalent Neck Disability Index measures and fewer revision surgeries for patients who received the Prestige Cervical Disc. Post-operative examination of the disc patients showed that they had a statistically superior overall neurological success rate at 24 months.

"As an active mom and an amateur triathlete, the Prestige Disc gave me back my life," said Stacey Brickson, a patient enrolled in the clinical study from Madison, WI. "I had so much pain and disability from an auto accident that I could not even lift my head off a pillow before I got the Prestige Disc, and I was too active to even think about a spinal fusion," she added.

As part of the FDA-approval conditions, Medtronic has agreed to conduct a seven-year post approval study to evaluate long-term safety and effectiveness. Medtronic is also going to perform a five-year enhanced surveillance study.

For more information: www.necksurgery.com or www.prestigedisc.com.

Related Content

Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to